Success Metrics

Active Trials

8(100%)

Phase Distribution

Ph phase_3

13%

Ph phase_1

25%

Ph phase_2

50%

Ph phase_4

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

2(25.0%)

Phase 2Efficacy & side effects

4(50.0%)

Phase 3Large-scale testing

1(12.5%)

Phase 4Post-market surveillance

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Detailed Status

Active, not recruiting4

Recruiting4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 4

Trials by Phase

Phase 12 (25.0%)

Phase 24 (50.0%)

Phase 31 (12.5%)

Phase 41 (12.5%)

Trials by Status

active_not_recruiting450%

recruiting450%

Recent Activity

8 active trials

Showing 5 of 8

active_not_recruitingphase_2

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

NCT05849298

active_not_recruitingphase_2

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

NCT06004661

active_not_recruitingphase_2

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07047118

recruitingphase_1

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

NCT07226986

recruitingphase_3

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT05849298Phase 2

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Active Not Recruiting

NCT06004661Phase 2

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Active Not Recruiting

NCT07047118Phase 2

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Active Not Recruiting

NCT07226986Phase 1

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Recruiting

NCT05939414Phase 3

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Recruiting

NCT05803941Phase 4

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Recruiting

NCT06894511Phase 2

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Active Not Recruiting

NCT06531499Phase 1

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

Recruiting

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8